NASDAQ
30.01.26 | 21:59
5,720 US-Dollar
-0,87 % -0,050
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| FOGHORN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.01. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium | 119 | GlobeNewswire (Europe) | WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases... ► Artikel lesen | |
| 13.01. | Foghorn Therapeutics stock reaffirmed as Buy by BTIG, named top pick for 1H26 | 3 | Investing.com | ||
| 12.01. | Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 target | 2 | Investing.com | ||
| 12.01. | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.01. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 | 447 | GlobeNewswire (Europe) | Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026 Phase... ► Artikel lesen | |
| 18.12.25 | BTIG stuft Foghorn Therapeutics mit "Buy" ein - Potenzial in der Krebs-Pipeline | 1 | Investing.com Deutsch | ||
| 18.12.25 | BTIG initiates Foghorn Therapeutics stock with Buy rating on cancer pipeline | 1 | Investing.com | ||
| 04.12.25 | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.12.25 | Stifel initiates Foghorn Therapeutics stock with Buy rating, $12 target | 1 | Investing.com | ||
| 07.11.25 | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.11.25 | Foghorn Therapeutics GAAP EPS of -$0.25 beats by $0.08, revenue of $8.15M beats by $1.95M | 6 | Seeking Alpha | ||
| 05.11.25 | Foghorn Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 30.10.25 | Foghorn advances protein degrader programs for cancer treatment | 1 | Investing.com | ||
| 30.10.25 | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs | 229 | GlobeNewswire (Europe) | - Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and degrades ARID1B; potentially relevant in up to 5% of all solid tumors... ► Artikel lesen | |
| 30.10.25 | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.10.25 | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit | 145 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases... ► Artikel lesen | |
| 05.08.25 | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update | 317 | GlobeNewswire (Europe) | FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track... ► Artikel lesen | |
| 25.03.25 | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting | 209 | GlobeNewswire (Europe) | - FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Oral presentation on preclinical... ► Artikel lesen | |
| 06.03.25 | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook | 211 | GlobeNewswire (Europe) | First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 314,30 | +0,01 % | H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 | ||
| NUVALENT | 102,89 | +0,45 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| NURIX THERAPEUTICS | 16,520 | -6,08 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 14,290 | -3,77 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 25,720 | -1,30 % | Olema Oncology Announces Departure of Chief Operating and Financial Officer | SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 65,42 | -6,52 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,520 | -0,92 % | How Harmony Biosciences Can Prove Its Skeptics Wrong | ||
| STRUCTURE THERAPEUTICS | 88,44 | +1,48 % | Structure Therapeutics gains on report suggesting it may be a top takeover target | ||
| SUMMIT THERAPEUTICS | 14,460 | -6,10 % | Summit Therapeutics: FDA akzeptiert Zulassungsantrag für Lungenkrebsmedikament Ivonescimab | ||
| TRAVERE THERAPEUTICS | 31,110 | -2,75 % | Block & Leviton LLP: Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses | Boston, Massachusetts--(Newsfile Corp. - January 16, 2026) - Block & Leviton is investigating Travere Therapeutics, Inc. (NASDAQ: TVTX) for potential securities law violations. Investors who have... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,58 | +0,01 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ERASCA | 10,525 | +2,09 % | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | ||
| ADMA BIOLOGICS | 17,300 | +1,70 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| ARVINAS | 13,380 | 0,00 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 13,670 | +1,03 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen |
FOGHORN THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,050 (-0,87 %) liegt der Kurs bei 5,720 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FOGHORN THERAPEUTICS INC finden Sie auf Wallstreet Online.